Tilray Brands (NASDAQ:TLRY – Get Free Report) is expected to announce its Q3 2026 results before the market opens on Wednesday, April 1st. Analysts expect Tilray Brands to post earnings of ($0.14) per share and revenue of $201.35 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earning overview page for the latest details on the call scheduled for Tuesday, April 7, 2026 at 8:30 AM ET.
Tilray Brands (NASDAQ:TLRY – Get Free Report) last released its earnings results on Thursday, January 8th. The company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.12. Tilray Brands had a negative net margin of 251.69% and a negative return on equity of 6.35%. The firm had revenue of $217.51 million during the quarter, compared to analysts’ expectations of $211.15 million. During the same period in the prior year, the company earned ($0.03) EPS. On average, analysts expect Tilray Brands to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Tilray Brands Price Performance
Shares of Tilray Brands stock opened at $6.54 on Friday. The company has a debt-to-equity ratio of 0.19, a current ratio of 2.81 and a quick ratio of 1.72. The company has a market cap of $761.96 million, a PE ratio of -0.30 and a beta of 1.96. The firm has a fifty day moving average price of $7.60 and a two-hundred day moving average price of $10.39. Tilray Brands has a fifty-two week low of $3.51 and a fifty-two week high of $23.20.
Hedge Funds Weigh In On Tilray Brands
Key Stories Impacting Tilray Brands
Here are the key news stories impacting Tilray Brands this week:
- Positive Sentiment: Tilray announced a licensing partnership with The Magnum Ice Cream Company to launch Popsicle® Hard ready-to-drink (5% ABV) beverages in the U.S., a nostalgic, CPG-focused play that can drive beverage revenue and expand mainstream distribution. Read More.
- Neutral Sentiment: Tilray set an April 1, 2026 pre-market release for Q3 fiscal results and will host an 8:30 AM ET webcast — a catalyst that could move the stock either direction depending on revenue, margins and guidance. Short-term volatility is likely around the print. Read More.
- Negative Sentiment: Market reaction has been negative today: coverage notes TLRY declined more than the market. The shares are trading below both the 50‑day ($7.60) and 200‑day ($10.39) moving averages and volume is below average, signaling technical weakness; near-term investor concern likely reflects uncertainty ahead of the earnings release. Read More.
Analyst Ratings Changes
A number of brokerages have recently commented on TLRY. Zacks Research raised shares of Tilray Brands from a “strong sell” rating to a “hold” rating in a research report on Wednesday, February 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Tilray Brands in a report on Wednesday, January 21st. Wall Street Zen upgraded shares of Tilray Brands from a “sell” rating to a “hold” rating in a research report on Saturday, March 21st. Roth Mkm reduced their price objective on Tilray Brands from $20.00 to $10.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 20th. Finally, ATB Cormark Capital Markets upgraded shares of Tilray Brands from a “strong sell” rating to a “hold” rating in a research report on Wednesday, December 10th. One equities research analyst has rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $13.33.
View Our Latest Stock Analysis on Tilray Brands
About Tilray Brands
Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.
Tilray’s product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.
See Also
Receive News & Ratings for Tilray Brands Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray Brands and related companies with MarketBeat.com's FREE daily email newsletter.
